Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib + Chemotherapy in Metastatic Pancreatic Cancer
NCT03649321Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bemcentinib in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Overall Response Rate. Started Jan 2019; status: terminated.
02
Drugs
bemcentinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03649321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649321.